Log In
Print
BCIQ
Print
Print this Print this
 

molindone (SPN-810)

  Manage Alerts
Collapse Summary General Information
Company Supernus Pharmaceuticals Inc.
DescriptionExtended-release formulation of molindone, an antipsychotic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat impulsive aggression in patients with ADHD; Treat impulsive aggression in pediatric patients with ADHD
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today